Previous studies have shown that HDAC1 and HDAC2 are frequently overexpressed in hepatocellular carcinoma and that higher expression levels are associated with poorer survival, suggesting their potential value as prognostic biomarkers and therapeutic targets in HCC (113, 114). The gene discussed is HDAC2; the disease is hepatocellular carcinoma.